Chinese venture capital (VC) firm Addor Capital announced on Tuesday the completion of its second health industry investment fund at 1.557 billion yuan ($240.8 million) to step up investments in emerging innovative drug developers in the country.
Addor said that the final closing of the new fund happened only two months after it had started the fundraising work. Limited partners (LPs) in this vehicle include government-guided funds, state-owned asset managers, high-net-worth individuals (HNWIs), as well as other healthcare-focused investors.
